1 March 2017 in Journal of Experimental Pharmacology
Natural compounds obtained from plants are capable of garnering considerable attention from the scientific community, primarily due to their ability to check and prevent the onset and progress of cancer. These natural compounds are primarily used due to their nontoxic nature and the fewer side effects they cause compared to chemotherapeutic drugs. Furthermore, such natural products perform even better when given as an adjuvant along with traditional chemotherapeutic drugs, thereby enhancing the potential of chemotherapeutics and simultaneously reducing their undesired side effects. Curcumin, a naturally occurring polyphenol compound found in the plant Curcuma longa, is used as an Indian spice. It regulates not only the various pathways of the immune system, cell cycle checkpoints, apoptosis, and antioxidant response but also numerous intracellular targets, including pathways and protein molecules controlling tumor progression. Many recent studies conducted by major research groups around the globe suggest the use of curcumin as a chemopreventive adjuvant molecule to maximize and minimize the desired effects and side effects of chemotherapeutic drugs. However, low bioavailability of a curcumin molecule is the primary challenge encountered in adjuvant therapy. This review explores different therapeutic interactions of curcumin along with its targeted pathways and molecules that are involved in the regulation of onset and progression of different types of cancers, cancer treatment, and the strategies to overcome bioavailability issues and new targets of curcumin in the ever-growing field of cancer.
18 May 2019 in The Nucleus
One of the major emerging modes of treatment for cancer patients in the current healthcare systems has been immunotherapy. Various approaches of immunotherapy have been proved to be useful against tumor progression in laboratory settings. Few have also been showing promising results in clinical trials. However, many clinical trials have also pointed out the adverse side effects of immunotherapy on tumor patients. In this context, we discuss about the success and failures of the present modes of immunotherapy available to patients and also about the emerging target points that are coming up and may be crucial in the success of future immunotherapy. The upcoming researches involving new players in the immunotherapy arena like Breg and Treg and how combinatorial therapies will be needed to counter the side effects that are exhibited by the present techniques of immunotherapy have been discussed in the review. This review will provide a broad picture of the current scenario of cutting edge immunotherapy and the newer methods that can be utilized to prevent the failures and ensure success in future clinical trials involving immunotherapy.